% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Ng:276761,
author = {C. H. Ng and D. Obrecht and O. Wells and M. Zapotocky and
D. Sumerauer and H. Coltin and D.-A. Khuong-Quang and D. D.
Eisenstat and K. M. Kinross and C. L. White and E. M. Algar
and A. Luck and H. Witt$^*$ and U. Schüller and M. Mynarek
and T. Pietsch and N. U. Gerber and M. Benesch and M.
Warmuth-Metz and R. Kortmann and B. Bison and M. D. Taylor
and S. Rutkowski and S. M. Pfister$^*$ and D. T. Jones$^*$
and N. G. Gottardo and K. von Hoff and K. Pajtler$^*$ and V.
Ramaswamy and J. R. Hansford},
title = {{A} multi-institutional retrospective pooled outcome
analysis of molecularly annotated pediatric supratentorial
{ZFTA}-fused ependymoma.},
journal = {Neuro-oncology advances},
volume = {5},
number = {1},
issn = {2632-2498},
address = {Oxford},
publisher = {Oxford University Press},
reportid = {DKFZ-2023-01142},
pages = {vdad057},
year = {2023},
abstract = {ZFTA-RELA (formerly known as c11orf-RELA) fused
supratentorial ependymoma (ZFTAfus ST-EPN) has been
recognized as a novel entity in the 2016 WHO classification
of CNS tumors and further defined in the recent 2021
edition. ZFTAfus ST-EPN was reported to portend poorer
prognosis when compared to its counterpart, YAP1 ST-EPN in
some previously published series. The aim of this study was
to determine the treatment outcome of molecularly confirmed
and conventionally treated ZFTAfus ST-EPN patients treated
in multiple institutions.We conducted a retrospective
analysis of all pediatric patients with molecularly
confirmed ZFTAfus ST-EPN patients treated in multiple
institutions in 5 different countries (Australia, Canada,
Germany, Switzerland, and Czechia). Survival outcomes were
analyzed and correlated with clinical characteristics and
treatment approaches.A total of 108 patients were collated
from multiple institutions in 5 different countries across
three continents. We found across the entire cohort that the
5- and 10-year PFS were $65\%$ and $63\%,$ respectively. The
5- and 10-year OS of this cohort of patients were $87\%$ and
$73\%.$ The rates of gross total resection (GTR) were high
with 84 out of 108 $(77.8\%)$ patients achieving GTR. The
vast majority of patients also received post-operative
radiotherapy, 98 out of 108 $(90.7\%).$ Chemotherapy did not
appear to provide any survival benefit in our patient
cohort.This is the largest study to date of
contemporaneously treated molecularly confirmed ZFTAfus
ST-EPN patients which identified markedly improved survival
outcomes compared to previously published series. This study
also re-emphasizes the importance of maximal surgical
resection in achieving optimal outcomes in pediatric
patients with supratentorial ependymoma.},
keywords = {ZFTA-RELA (Other) / central nervous system tumors (Other) /
molecular (Other) / pediatric (Other) / supratentorial
ependymoma (Other)},
cin = {B062 / B360},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)B360-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37287693},
pmc = {pmc:PMC10243832},
doi = {10.1093/noajnl/vdad057},
url = {https://inrepo02.dkfz.de/record/276761},
}